Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool May 7, 2008 Brian Orelli	Teva's on a Tear The generic-drug maker can't be stopped.
The Motley Fool July 28, 2009 Brian Orelli	All Growth, All the Time This generic-drug maker is no value play.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool December 26, 2007 Brian Orelli	Teva's Heartburning Battle Teva launches its generic version of Wyeth's and Altana's heartburn medication, Protonix; those companies attempt to get a preliminary injunction. There are high stakes on both sides of the dispute.
The Motley Fool July 30, 2008 Brian Orelli	Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest.
The Motley Fool February 18, 2009 Brian Orelli	Teva Raises the Barr Generic drugs are likely to be a major solution that governments use to tackle the problem of rising health-care costs, and the new, larger Teva looks well-poised to grab that growth as it happens.
The Motley Fool September 22, 2009 Robert Steyer	Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge.
The Motley Fool May 5, 2010 Brian Orelli	Teva's Double-Edged Sword Nice quarter, but where will future growth come from?
The Motley Fool February 28, 2006 Stephen D. Simpson	Still Waiting for Teva to Stumble This leading Israeli generics firm hasn't seen a stock pullback of any consequence since mid- to late 2004. And while fourth-quarter results weren't fabulous, they were good enough given the circumstances
The Motley Fool October 31, 2007 Brian Orelli	From Apples to Apple Pie at Teva Year-over-year sales skyrocket at Teva Pharmaceutical, due to the launch of more than 25 new products. Investors, take note.
The Motley Fool November 7, 2008 Brian Orelli	Teva's Steady Growth Generic-drug maker Teva Pharmaceuticals has been a good defensive play during the severe downturn in the market.
The Motley Fool May 22, 2008 Brian Orelli	Wyeth's Never-Ending Generic Woes Novartis jumps on the generic Protonix bandwagon.
The Motley Fool November 8, 2006 Brian Lawler	Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong.
The Motley Fool January 31, 2008 Brian Orelli	Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.
The Motley Fool June 11, 2008 Brian Orelli	Mylan Takes Generic Aim at Teva Mylan licenses a generic version of Teva's MS drug, Copaxone. Investors, take note.
The Motley Fool November 8, 2005 Stephen D. Simpson	Teva Is No Generic Generics Firm Although 2005 wasn't a great year for generics on the whole, 2006 is shaping up to be pretty interesting for Teva. Is it time to buy these shares?
The Motley Fool August 1, 2005 Stephen D. Simpson	Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance.
The Motley Fool November 3, 2009 Brian Orelli	Nice Quarter, Teva. What Will You Buy Next? Branded or generic, it's always a tough call.
The Motley Fool September 15, 2008 Brian Orelli	Teva and FDA's Never-Ending Court Battle The Food and Drug Administration has won the latest installment of its grudge match with Teva Pharmaceuticals over the 180-day exclusivity period for generic versions of Johnson & Johnson's Risperdal.
The Motley Fool March 28, 2008 Brian Orelli	Wyeth Fires to Get Back on Fire The first round of Wyeth's cuts look like the right move for the big pharma company.
The Motley Fool July 14, 2008 Brian Orelli	Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone.
The Motley Fool July 25, 2008 Brian Orelli	Generic Heartburn at Wyeth Revenue from its heartburn drug Protonix dropped 59% year over year after Teva Pharmaceuticals and Sun Pharmaceuticals launched their generic versions of the drug.
The Motley Fool April 11, 2008 Brian Orelli	Teva Tugs at Both Ends of the MS String Teva tries to get multiple sclerosis patients to switch to its drug.
The Motley Fool February 17, 2010 Brian Orelli	This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool April 23, 2008 Brian Orelli	Wyeth Recovers From Its Heartburn Wyeth deals with generic competition for one of its biggest drugs.
The Motley Fool March 19, 2009 Brian Orelli	Teva: An Equal-Opportunity Bully Making money by picking on the little guy, too.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool May 5, 2009 Brian Orelli	Generic Growth, Acquisition Style Sales at Teva Pharmaceuticals were up 22% year over year, but don't bust out the champagne just yet.
The Motley Fool July 1, 2008 Brian Orelli	As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
The Motley Fool September 11, 2007 Brian Orelli	Teva Spending Plenty of Time in Court Three patent disputes in one week keeps the lawyers busy: Teva and Novartis have been locked in dispute over Novartis' Famvir tablets... Teva and Forest spar over patents for Lexapro... Teva and Wyeth argue over Protonix...
The Motley Fool February 11, 2010 Brian Orelli	A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid.
The Motley Fool November 26, 2008 Brian Orelli	Teva and AstraZeneca's Drama Concludes Teva and AstraZeneca settle a lawsuit, but investors are still left in the dark.
The Motley Fool July 8, 2008 Brian Orelli	Not Teva's Forte Teva Pharmaceutical's Copaxone for multiple sclerosis fails to show a benefit at double strength. Investors take note.
The Motley Fool August 8, 2006 Stephen D. Simpson	Nothing Generic About Teva's Performance Once again, buying this this Israeli generics giant on dips returns a tidy profit.
The Motley Fool June 30, 2005 Brian Gorman	Teva's Non-Generic Side The drug company is working hard to cement its position in the market for multiple sclerosis meds. Investors, take note.
The Motley Fool May 15, 2008 Brian Orelli	Wanted: FDA Approval -- Pronto Teva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch.
The Motley Fool November 2, 2010 Travis Hoium	Momenta Pharmaceuticals Shares Plunged: What You Need to Know Momenta Pharmaceuticals shares fell 10% in trading early Tuesday after Teva Pharmaceutical Industries said it expects FDA approval this year on a drug to compete with Momenta's enoxaparin.
The Motley Fool November 5, 2004 Roger Nusbaum	The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool August 28, 2007 Brian Orelli	Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note.
The Motley Fool August 27, 2008 Brian Orelli	Teva Tells It Like It Is For Teva Pharmaceuticals, the details only confirmed the great initial report of the clinical trial success for its Parkinson's disease treatment Azilect.
The Motley Fool June 27, 2007 Billy Fisher	Improving Morale at Barr Preliminary OK of Barr Pharmaceutical's generic antidepressant perks up the stock's potential.
The Motley Fool April 14, 2008 Brian Orelli	Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool June 28, 2011 Eric Bleeker	Where Is Teva Pharmaceuticals Finding Growth? Teva should see its sales continue to climb, especially in already booming international markets.
The Motley Fool November 2, 2010 Eric Dutram	Tuesday's ETF to Watch: iShares Israel ETF (EIS) TEVA reports earnings.